Skip to main content

Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the Jefferies 2025 London Healthcare Conference on Tuesday, November 18 at 2:00 p.m. GMT / 9:00 a.m. ET / 6:00 a.m. PT in London, United Kingdom.

A live webcast of the presentation will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days.

About Vir Biotechnology

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a portfolio of preclinical programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  204.46
-5.65 (-2.69%)
AAPL  269.06
+4.48 (1.69%)
AMD  196.24
-3.91 (-1.95%)
BAC  51.24
-1.82 (-3.42%)
GOOG  314.57
-0.33 (-0.10%)
META  644.04
-11.62 (-1.77%)
MSFT  387.02
-10.21 (-2.57%)
NVDA  191.42
+1.60 (0.84%)
ORCL  139.65
-8.43 (-5.69%)
TSLA  396.61
-15.21 (-3.69%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.